These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7570508)

  • 41. Correlation of cytosolic concentrations of ER, PS2, Cath-D, TPS, TK and cAMP in primary breast carcinomas.
    Kausitz J; Kuliffay P; Pecen L; Eben K; Puterová B
    Neoplasma; 1994; 41(6):331-6. PubMed ID: 7870216
    [TBL] [Abstract][Full Text] [Related]  

  • 42. pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response.
    Henry JA; Piggott NH; Mallick UK; Nicholson S; Farndon JR; Westley BR; May FE
    Br J Cancer; 1991 Apr; 63(4):615-22. PubMed ID: 1850611
    [TBL] [Abstract][Full Text] [Related]  

  • 43. pS2 protein status fails to be an independent prognostic factor in an average breast cancer population.
    Speiser P; Stolzlechner J; Haider K; Heinzl H; Jakesz R; Pecherstorfer M; Rosen H; Sevelda P; Zeilliger R
    Anticancer Res; 1994; 14(5B):2125-30. PubMed ID: 7840511
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Estrogen receptor analysis on biopsies and fine-needle aspirates from human breast carcinoma. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.
    Reiner A; Spona J; Reiner G; Schemper M; Kolb R; Kwasny W; Függer R; Jakesz R; Holzner JH
    Am J Pathol; 1986 Dec; 125(3):443-9. PubMed ID: 3541638
    [TBL] [Abstract][Full Text] [Related]  

  • 45. pS2 is an independent prognostic factor for post-relapse survival in primary breast cancer.
    Jansen RL; Hupperets PS; Arends JW; Joosten-Achjanie SR; Volovics A; Hillen HF; Schouten HC
    Anticancer Res; 1998; 18(1B):577-82. PubMed ID: 9568180
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relationships between cathepsin-D, pS2 protein and hormonal receptors in breast cancer cytosols: inconsistency with their established prognostic significance.
    Ardavanis A; Gerakini F; Amanatidou A; Scorilas A; Pateras C; Garoufali A; Pissakas G; Stravolemos K; Apostolikas N; Yiotis I
    Anticancer Res; 1997; 17(5A):3665-9. PubMed ID: 9413220
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prediction of relapse and survival in breast cancer patients by pS2 protein status.
    Foekens JA; Rio MC; Seguin P; van Putten WL; Fauque J; Nap M; Klijn JG; Chambon P
    Cancer Res; 1990 Jul; 50(13):3832-7. PubMed ID: 2354435
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Determination of estrogen receptor status in breast cancer by immunocytochemical examination of fine-needle aspirates].
    Balslev E; Nielsen M; Jensen OJ; Francis D; Thorpe SM
    Ugeskr Laeger; 1992 Nov; 154(48):3395-8. PubMed ID: 1462448
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relationships between tamoxifen binding proteins in primary breast cancer biopsies.
    Marsigliante S; Leo G; D'Elia M; Vinson GP; Greco S; Puddefoot J; Storelli C
    Eur J Cancer; 1994; 30A(11):1694-700. PubMed ID: 7833146
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oestrogen receptor assay of breast cancer by immunocytochemistry of fine needle aspirates.
    Kitchen PR; Stillwell RG; Henderson MA; Bennett RC; Rennie GC; Kou SJ; Georgiou T; Ayberk H
    Aust N Z J Surg; 1991 Mar; 61(3):223-8. PubMed ID: 1848428
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Breast cancer-associated protein pS2 expression in tumors of the biliary tract.
    Seitz G; Thelsinger B; Tomasetto G; Rio MC; Chambon P; Blin N; Welter G
    Am J Gastroenterol; 1991 Oct; 86(10):1491-4. PubMed ID: 1928043
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunocytochemical staining of pS2 protein in fine-needle aspirate from breast cancer is an accurate guide to response to tamoxifen in patients aged over 70 years.
    Wilson YG; Rhodes M; Ibrahim NB; Padfield CJ; Cawthorn SJ
    Br J Surg; 1994 Aug; 81(8):1155-8. PubMed ID: 7953346
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunohistochemical determination of pS2 in invasive breast carcinomas: a study on 942 cases.
    Soubeyran I; Wafflart J; Bonichon F; de Mascarel I; Trojani M; Durand M; Avril A; Coindre JM
    Breast Cancer Res Treat; 1995 May; 34(2):119-28. PubMed ID: 7647329
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessing estrogen and progesterone receptor status in fine needle aspirates from breast carcinomas. Results on six years of material and correlation with biochemical assay.
    Sauer T; Beraki E; Jebsen PW; Amlie E; Harbitz T; Kåresen R; Naess O
    Anal Quant Cytol Histol; 1998 Apr; 20(2):122-6. PubMed ID: 9569969
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of a breast-cancer-associated protein (pS2) in human neuro-endocrine tumours.
    Wang DG; Johnston CF; Liu WH; Sloan JM; Buchanan KD
    Int J Cancer; 1997 Jun; 74(3):270-4. PubMed ID: 9221803
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Estrogen and progesterone receptors and pS2 and ERD5 antigens in gastric carcinomas from the European population.
    Chaubert P; Bouzourene H; Saraga E
    Mod Pathol; 1996 Mar; 9(3):189-93. PubMed ID: 8685212
    [TBL] [Abstract][Full Text] [Related]  

  • 57. First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer.
    Helms MW; Packeisen J; August C; Schittek B; Boecker W; Brandt BH; Buerger H
    J Pathol; 2005 Jul; 206(3):366-76. PubMed ID: 15892165
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa.
    Rio MC; Bellocq JP; Daniel JY; Tomasetto C; Lathe R; Chenard MP; Batzenschlager A; Chambon P
    Science; 1988 Aug; 241(4866):705-8. PubMed ID: 3041593
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Retrospective analysis of prognostic significance of the estrogen-inducible pS2 gene in male breast carcinoma.
    Kardaś I; Seitz G; Limon J; Niezabitowski A; Ryś J; Theisinger B; Welter C; Blin N
    Cancer; 1993 Sep; 72(5):1652-6. PubMed ID: 8394203
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR.
    Charpin C; Bonnier P; Khouzami A; Vacheret H; Andrac L; Lavaut MN; Allasia C; Piana L
    Anticancer Res; 1992; 12(3):591-7. PubMed ID: 1352440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.